Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders

Introduction

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory central nervous system disease that preferentially affects the optic nerve and spinal cord [Wingerchuk et al. 2015]. Up to 70% of patients with NMOSD have antibodies to aquaporin-4 (AQP4-IgG). AQP4 is expressed in astrocytes of the optic nerve and Müller cells in the eye. A subgroup of AQP4-IgG-seronegative patients has antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG), and optic neuritis (ON) relapses are also frequent in these patients [Höftberger et al. 2015].

We hypothesize that retinal injury may be additionally driven by Müller cells dysfunction in patients with AQP4-IgG. This condition, in contrast with those patients who harbour MOG-IgG, may induce differential changes in the outer retinal layers. In this brief series of cases, we aim to investigate if optical coherence tomography (OCT) may distinguish ON associated with AQP4-IgG or MOG-IgG in NMOSD.

Methods

We included 15 ON eyes from five patients diagnosed with NMOSD and AQP4-IgG and four patients who fulfilled the new diagnostic criteria for NMOSD without AQP4-IgG [Wingerchuk et al. 2015] and who had MOG-IgG. AQP4-IgG and MOG-IgG were tested by cell-based assays as reported [Höftberger et al. 2015]. The presence of prior ON was assessed following international guidelines [Petzold et al. 2014]. Patients suffered bilateral ON, except for one patient in each group who only developed a unilateral ON. In addition, one ON eye of a patient with MOG-IgG was excluded due to the low quality of the OCT scan. Thus, we included 15 NMOSD–ON eyes (nine ON eyes with AQP4-IgG and six ON eyes with MOG-IgG). As a group of comparison, we selected 15 ON eyes of 15 MS patients with at least one prior ON episode (MS–ON eyes). We retrieved the MS patients whose age better matched NMOSD patients’ age from our general data set of MS patients (nine matched with AQP4-IgG-seropositive patients and six with MOG-IgG-seropositive patients). The period of time from the last ON episode to the visual examination was at least six months for all cases. Patients gave consent to participate, and the institutional review board of the Hospital Clinic, University of Barcelona, Spain, approved the study.

We evaluated visual acuity, colour vision and visual fields as previously described [Martínez-Lapiscina et al. 2014]. The retinal scans were performed using a Spectralis® SD-OCT device (Spectralis® Heidelberg Engineering, Heyex 5.30) by a trained technician under standard ambient light conditions and without pupillary dilatation, using eye-tracking modality. Correction for spherical errors was adjusted prior to each measurement. The peripapillary retinal nerve fibre layer (pRNFL) thickness (μm) was measured using a ring scan of 12 degrees of diameter, automatically centred on the optic nerve head (100 ART; 1536 A scans per B scan). The macular scan protocol was a 20 × 20 degree raster scan (horizontal orientation) centred on the fovea, including 25 high-resolution B scans (ART⩾9; 512 A scans per B scan). A single masked grader performed intraretinal layer segmentation using the same standard 6.0c version of the Spectralis segmentation algorithm in a semi-automated fashion, with manual correction of obvious errors to quantify macular ganglion cell complex (mGCC) including the retinal nerve fibre; ganglion cell and inner plexiform layers; inner nuclear layer (INL); outer plexiform layer (OPL); outer nuclear layer (ONL) and photoreceptors (PR) including retinal pigment epithelium retinal and Bruch membrane.

We separately included both NMOSD–ON eyes of each patient, rather than using the mean of both eyes, because even though some studies showed a mild retinal injury in non-ON eyes in NMOSD [Monteiro et al. 2012], a recent review suggested that the visual impairment in NMOSD is basically attributable to the ON episodes [Bennett et al. 2015]. Using the Mann–Whitney U test, we compared visual outcomes in the two groups and thereafter, we repeated analyses stratifying by antibody status. Two-tailed p values <0.05 were considered significant. Analyses were performed with the statistical package IBM-SPSS 20.0 software.

Results

We did not find significant differences in sex, age, number of ON episodes, and median time between last ON and visual examination in NMOSD–ON and MS–ON eyes in our study. NMOSD–ON eyes displayed poorer visual outcomes compared with MS–ON, although differences were only significant for low-contrast visual acuity. NMOSD–ON eyes displayed thinner pRNFL compared with MS–ON eyes. NMOSD–ON eyes showed thinner OPL and thicker ONL compared with MS–ON eyes (data not shown). We did not find microcystic macular oedema in any of the ON eyes.

Table 1 shows visual outcomes for NMOSD–ON eyes. Patients with MOG-IgG were older than patients with anti-AQP4 antibodies. Therefore, to avoid the influence of the age in the visual outcomes, both groups of NMOSD patients, according to the antibody serostatus, were age-matched with MS–ON eyes. Compared with MS–ON eyes, only ON eyes of patients with AQP4-IgG displayed thinner pRNFL. Additionally, they showed thicker INL, thinner OPL and thicker ONL. However, we did not find differences in OCT thicknesses between ON eyes of patients with MOG-IgG and MS–ON eyes.

Table 1.

Comparison of visual outcomes between NMOSD–ON eyes with AQP4-IgG and MOG-IgG and age-matched MS–ON eyes.

	AQP4+ NMOSD–ON eyes[1]	MS–ON eyes[2]	p value[1–2]	MOG+ NMOSD–ON eyes[3]	MS–ON eyes[4]	p value[3–4]
Sex n [%] (female)	6 [66%]	7 [77%]	0.910	3 [50%]	2 [33%]	0.558
Age (years)	34.9 [19.4–43.8]	32.6 [27.6–36.7]	0.965	54.4 [53.4–58.1]	49.7 [42.2–61.5]	0.240
Number of ON	2 [1–3.5]	2 [1–2]	0.352	1.5 [1–4]	2 [1–2.25]	0.932
Time since last ON (months)	86.4 [15.2–107.3]	28.1 [14.1–100.2]	0.436	99.0 [21.4–185.8]	139.1 [69.1–169.6]	0.485
HCVA (#0-70 letters)	45 [28–64]	58 [50–60]	0.565	47 [40–56]	55 [41–56]	0.310
2.5% LCVA (#0-70 letters)	0 [0–20]	21 [3–30]	0.159	13 [0–30]	27 [0–30]	0.662
1.25% LCVA (#0-70 letters)	0 [0–0]	4 [0–20]	0.031	0 [0–6]	10 [0–18]	0.247
HRR (#0-36 symbols)	21 [6–36]	36 [29–36]	0.052	35 [17–36]	31 [12–35]	0.329
Visual field (MD) (dB)	−5.9 [−12.5 to −0.5]	−4.3 [−6.5 to −2.2]	0.831	−2.7 [−4.7 to −1.9]	−2.5 [−6.6 to −1.7]	0.841
pRNFL thickness (µm)	50 [40–77]	80 [72–90]	0.038	68 [48–78]	74 [65–78]	0.310
mGCC thickness (µm)	67 [62–100]	91 [78–99]	0.112	82 [62–93]	83 [65–92]	0.872
INL thickness (µm)	43 [42–46]	39 [37–42]	0.021	40 [37–41]	40 [40–42]	0.565
OPL thickness (µm)	30 [29–33]	35 [32–38]	0.008	30 [28–37]	32 [30–36]	0.626
ONL thickness (µm)	80 [78–81]	71 [65–75]	0.021	75 [68–80]	76 [71–81]	0.872
PR thickness (µm)	80 [78–81]	82 [80–84]	0.190	81 [77–83]	82 [80–86]	0.416

Data represents median [P25–P75] unless otherwise indicated. Chi-squared Pearson test for categorical variables and Mann–Whitney U test for quantitative variables.

AQP4⁺: antibodies against Aquaporin 4; HCVA: high contrast visual acuity; HRR: Hardy, Rand and Rittler pseudoisochromatic plates; INL: macular inner nuclear layer; LCVA: low contrast visual acuity; MD: mean deviation; mGCC: macular ganglion cell complex; MOG⁺: antibodies against myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; NMOSD: neuromyelitis optica spectrum disorder; OCT: optical coherence tomography; ON: optic neuritis; ONL; macular outer nuclear layer; OPL: macular outer plexiform layer; PR: photoreceptors including retinal pigment epithelium and Bruch membrane; pRNFL: peripapillary retinal nerve fibre layer.

Discussion

The OCT findings of our comparative study highlight important observations. First, serostatus stratification in NMOSD is important, because a different type of retinal cell damage may occur in patients with NMOSD who share a similar clinical phenotype but have a different antibody profile. Second, ON eyes of patients with AQP4-IgG displayed a distinguished outer retinal OCT macular phenotype (OPL thinning and ONL thickening). Third, OCT results of ON eyes of patients with MOG-IgG were similar to those found with MS–ON eyes.

Previous studies found that NMOSD–ON eyes typically displayed thinner pRNFL and mGCC as compared with MS–ON eyes [Bennett et al. 2015]. However, the evidence of involvement of other layers was scarce. Previous studies have described INL thickening in patients with NMOSD compared with MS [Fernandes et al. 2013] and OPL thinning with ONL thickening compared with isolated ON eyes and MS eyes [Park et al. 2014]. However, none of these studies analyzed these findings according to the antibody serostatus in patients with NMOSD.

The novelty of this brief study is that we addressed differences in NMOSD according to serostatus and the results suggest that even the clinical profile is similar, pathophysiological mechanisms underlying neuroaxonal damage are different in these two entities. In Figure 1, we discuss several biological processes that may explain the changes in outer retinal layers in ON eyes when associated with AQP4-IgG. INL thickening has been described in ON eyes of patients with MS. Some authors have proposed that INL thickening and microcystic macular oedema may be a continuum and represents trans-syntactic degeneration in the retina [Saidha et al. 2012]. However, we suggest that antibody-mediated damage of Müller cells is likely a key and specific contributor to the outer retinal damage observed in patients with AQP4-IgG. Moreover, the absence of differences between patients with ON associated with MOG-IgG or MS suggests that the physiopathological mechanism involved in both disorders may be similar. In fact, a MS-type pattern II was found in a recent histopathological study of one patient with MOG-IgG [Spadaro et al. 2015]. Altogether, this suggests that the neuroaxonal injury may be driven by different mechanisms: astrocytopathy for AQP4+ NMOSD and oligodendropathy for MOG+ NMOSD and MS patients.

Figure 1.

Pathogenic models of retinal damage in NMOSD–ON eyes.

In conclusion, OCT seems to be a useful tool to evaluate the underlying retinal damage related to the different serostatus in patients with NMOSD; however, larger and longitudinal studies are needed to confirm the results of the current exploratory study.